ClinicalTrials.gg
Not yet recruitingNCT07862569Updated Oct 7, 2026

DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg

A Phase 2 interventional study of DOR/ISL in HIV-1 and HIV Infection, sponsored by Merck Sharp & Dohme LLC. Not yet recruiting. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in HIV Infections by Merck & Co., Inc — 1 open to participants now, 2 under way, 1 of them phase 3. HIV Infections · Merck & Co., Inc.

Planned enrollment
46th of 66
45 · median 163
Started
2026
the only one that year
Phase 2
25 of 75
1 open now
Registered
75th of 75
by date

Among the 75 studies in HIV Infections by Merck & Co., Inc, this one is the 46th largest by planned enrollment of the 66 interventional ones that give a count, is the only one that started in 2026, is one of 25 in phase 2, and was the 75th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 75 studies in HIV Infections by Merck & Co., Inc is open now.

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: Up to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in HIV Infections by Merck & Co., Inc, or all of them as a file.
02

Study summary

This is a phase 2 study of the pharmacokinetics, safety, and efficacy of oral doravirine/islatravir (100 mg/0.25 mg) [MK-8591A] in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection who are virologically suppressed or treatment-naive.

The Base Study will last from Day 1 to Week 96. At Week 96, participants will be given the option to participate in an optional Study Extension and receive DOR/ISL until Week 240 or until it becomes commercially accessible, whichever is first.

03

Conditions studied

  • HIV-1
  • HIV Infection

Browse trials for

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric participant with -1 \<18 years of age
  • Body weight ≥35 kg
  • Is TN (HIV-1 positive with plasma HIV-1 RNA ≥500 copies/mL) or VS (HIV-1 positive at screening with plasma HIV-1 RNA \<50 copies/mL AND has received stable, continuous 2- or 3-drug antiretroviral therapy (ART) for ≥3 months prior to providing )

Exclusion criteria

Exclusion Criteria:

  • -2 infection
  • Hypsensitivity/ to any components of study medication or as determined by the investigator
  • Has an active diagnosis of hepatitis due to any cause
  • history of ≤5 years prior to signing except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or cutaneous Kaposi's sarcoma
  • Has a history or current evidence of any condition (including active tuberculosis infection, COVID-19, or other infections), therapy, laboratory abnormality, or other circumstance (including drug or alcohol use or dependence) that might, in the opinion of the investigator, confound the results of the study
  • Is taking or is anticipated to require systemic therapy, immune modulators, or any prohibited therapies
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    DOR/ISL

    Participants receive DOR/ISL 100 mg/0.25 mg once daily (qd) for 96 weeks. Participants will have the option to participate in the Study Extension and receive DOR/ISL until Week 240 or it becomes commercially available, whichever is first.

    Drug: DOR/ISL

Interventions

  • DrugDOR/ISL

    Drug pages: Doravirine · Islatravir

    DOR/ISL 100 mg/0.25 mg tablet taken by mouth qd

    Also known as: MK-8591A

06

What researchers measure

Primary outcomes

  1. Area under the plasma conentration-time curve from dosing to 24 hours postdose (AUC0-24) of ISL

    The plasma AUC0-24 will be assessed.

    Time frame: At designated timepoints on Day 28

  2. Maximum plasma concentration (Cmax) of ISL

    The plasma Cmax will be assessed.

    Time frame: At designated timepoints on Day 28

  3. Time to maximum plasma concentration (Tmax) of ISL

    The plasma Tmax will be assessed.

    Time frame: At designated timepoints on Day 28

  4. Apparent plasma terminal half-life (t½) of ISL

    The plasma t½ will be assessed.

    Time frame: At designated timepoints on Day 28

  5. Apparent clearance (CL/F) of ISL

    The CL/F will be assessed.

    Time frame: At designated timepoints on Day 28

  6. Volume of distribution (Vz/F) of ISL

    The Vz/F will be assessed.

    Time frame: At designated timepoints on Day 28

  7. Percentage of participants with ≥1 adverse event (AE) through Week 24

    The percentage of participants with AE(s) will be assessed.

    Time frame: Up to ~24 weeks

  8. Percentage of participants discontinuing from study therapy due to AE(s) through Week 24

    The percentage of participants discontinuing from therapy due to AE(s) will be assessed.

    Time frame: Up to ~24 weeks

Secondary outcomes

  1. Percentage of participants with ≥1 AE through Week 96

    The percentage of participants with AE(s) will be assessed.

    Time frame: Up to 96 weeks

  2. Percentage of participants discontinuing from study therapy due to AE(s) through Week 96

    The percentage of participants with AE(s) will be assessed.

    Time frame: Up to 96 weeks

  3. Percentage of virologically-suppressed (VS) participants with Human Immunodeficiency Virus Type 1 (HIV-1) ribonucleic acid (RNA) ≥50 copies/mL

    The percentage of VS participants with HIV-1 RNA ≥50 copies/mL will be assessed.

    Time frame: Weeks 24, 48, and 96

  4. Percentage of VS participants with HIV-1 RNA <50 copies/mL

    The percentage of VS participants with HIV-1 RNA \<50 copies/mL will be assessed.

    Time frame: Weeks 24, 48, and 96

  5. Percentage of VS participants with HIV-1 RNA <200 copies/mL

    The percentage of VS participants with HIV-1 RNA \<200 copies/mL will be assessed.

    Time frame: Weeks 24, 48, and 96

  6. Percentage of treatment-naive (TN) participants with HIV-1 RNA <50 copies/mL

    The percentage of TN participants with HIV-1 RNA \<50 copies/mL will be assessed.

    Time frame: Weeks 24, 48, and 96

  7. Percentage of TN participants with HIV-1 RNA <200 copies/mL

    The percentage of TN participants with HIV-1 RNA \<200 copies/mL will be assessed.

    Time frame: Weeks 24, 48, and 96

  8. Change from baseline in CD4+ T-cell counts in VS and TN participants

    The change from baseline in CD4+ T-cell counts will be assessed in VS and TN participants.

    Time frame: Weeks 24, 48, and 96

  9. Percentage of participants with viral drug resistance to DOR or ISL

    The percentage of participants with viral resistance-associated substitutions will be assessed during Weeks 24, 48, 96, and 144.

    Time frame: Weeks 24, 48, 96, and 144

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Sep 2029, 33 months later.

Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's planned 33 months is above that.

Counting every sponsor, half of 99 studies reached it within 31 months; a quarter within 17 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2026
First posted
Oct 7, 2026
StartEst.
Dec 23, 2026
Primary completionEst.
Sep 24, 2029
CompletionEst.
Dec 23, 2033
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07862569
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Dec 23, 2026 (estimated)
Primary completion
Sep 24, 2029 (estimated)
Completion
Dec 23, 2033 (estimated)
Last update
Oct 7, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doravirine · Islatravir

Start the discussion